In summary, these in vivo data support our in vitro observations and suggest that VEGF drives an immunosuppressive phenotype in tumor-specific VEGFR2+ myeloid cells and that blockade of VEGF activation of VEGFR2 on myeloid cells can reduce myeloid immunosuppressive function. Here, VEGFA is linked to neoplasm.